CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,513 | -43.2% | 1,564 | -65.6% | 0.00% | -66.7% |
| Q2 2023 | $81,883 | +264038.7% | 4,544 | +135.8% | 0.00% | +200.0% |
| Q1 2023 | $31 | +82.4% | 1,927 | +109.9% | 0.00% | 0.0% |
| Q4 2022 | $17 | -100.0% | 918 | -91.0% | 0.00% | -66.7% |
| Q3 2022 | $200,000 | +138.1% | 10,189 | +126.3% | 0.00% | +50.0% |
| Q2 2022 | $84,000 | -77.2% | 4,502 | -73.1% | 0.00% | -50.0% |
| Q1 2022 | $368,000 | +268.0% | 16,744 | +376.0% | 0.00% | +100.0% |
| Q4 2021 | $100,000 | +26.6% | 3,518 | -6.6% | 0.00% | 0.0% |
| Q3 2021 | $79,000 | +119.4% | 3,765 | +99.8% | 0.00% | +100.0% |
| Q2 2021 | $36,000 | +260.0% | 1,884 | +189.4% | 0.00% | – |
| Q1 2021 | $10,000 | -88.4% | 651 | -89.3% | 0.00% | -100.0% |
| Q4 2020 | $86,000 | -76.0% | 6,073 | -73.5% | 0.00% | -25.0% |
| Q3 2020 | $359,000 | +519.0% | 22,884 | +593.0% | 0.00% | +100.0% |
| Q2 2020 | $58,000 | +45.0% | 3,302 | +22.7% | 0.00% | -33.3% |
| Q3 2019 | $40,000 | +233.3% | 2,691 | +441.4% | 0.00% | +200.0% |
| Q2 2019 | $12,000 | -50.0% | 497 | -53.5% | 0.00% | 0.0% |
| Q1 2019 | $24,000 | -55.6% | 1,069 | -40.9% | 0.00% | -75.0% |
| Q4 2018 | $54,000 | – | 1,808 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |